HANSOH PHARMA (03692): HS-10561 Capsules obtained a drug clinical trial approval notice issued by the National Medical Products Administration.

HANSOH PHARMA (03692) announced that on February 24, 2025, the group has entered into a collaboration with Guangzhou Lupeng Pharmaceutical Co., Ltd. for a type 1 small molecule Bruton's tyrosine kinase inhibitor (BTKi) HS-10561 capsule. The drug has received the drug clinical trial approval notification from the National Medical Products Administration (NMPA) of China, and is intended to be used in clinical trials for chronic spontaneous urticaria.